Last publications
Dendritic Cells Require TMEM176A/B Ion Channels for Optimal MHC Class II Antigen Presentation to Naive CD4 + T Cells
Mélanie Lancien, Géraldine Bienvenu, Lucile Guéno, Emmanuel Merieau, Severine Remy, Amandine Even, Aurelie Moreau, Alice Molle, Cynthia Fourgeux, Flora Coulon, Gaelle Bériou, Laurence Bouchet-Delbos, Elise Chiffoleau, Peggy Kirstetter, Susan Chan, Steven Kerfoot, Saeed Abdu Rahiman, Veronica de Simone, Gianluca Matteoli, Gaëlle Boncompain 1, 2, Franck Perez 1, 2, Régis Josien 3 , Jérémie Poschmann, Maria Cristina Cuturi, 4, 5, 3 Cédric Louvet.1 Institut Curie [Paris]
2 Biologie Cellulaire et Cancer
3 U1064 Inserm - CRTI - Centre de Recherche en Transplantation et Immunologie
4 UN - Université de Nantes
5 CHU Nantes - Centre hospitalier universitaire de Nantes
J Immunol. 2021 Jul 7;ji2000498. doi: 10.4049/jimmunol.2000498.
The diversity of the plasmablast signature across species and experimental conditions : a meta-analysis
Alexis Grasseaua, Marina Boudigoua, Magalie Michée- Cospolitea, Céline Delaloyb, Olivier Mignena, Christophe Jamina,c, Divi Corneca,c, Jacques- Olivier Persa,c,
Laëtitia Le Pottiera, Sophie Hilliona,
a UMR1227, LBAI, INSERM, Univ Brest,Brest, France
b UMR U1236, INSERM, Etablissement Français du Sang (EFS) de Bretagne, Université de Rennes 1, Rennes, France
c UMR1227, LBAI, INSERM, CHU de Brest, Univ Brest, Brest, France
Phase I/II clinical trial of adoptive cell transfer of sorted specific T cells for metastatic melanoma patients
Brigitte Dréno1,2,3,4,5, Amir Khammari1,3,4,5, Agnès Fortun3,4, Virginie Vignard3,4,5,Soraya Saiagh2, Tiffany Beauvais3,4,5, Nicolas Jouand4,6, Sylvain Bercegay2, Sylvain Simon3,4, François Lang3,4 & Nathalie Labarrière3,4,6
1 Dermato‑Cancerology Department, CIC 1413, CHU Nantes, Nantes, France
2 UTCG, CHU Nantes, Nantes, France
3 CRCINA, Inserm, Université de Nantes, 44000 Nantes, France
4 LabEx IGO “Immunotherapy, Graft, Oncology”, Nantes, France
5 CHU Nantes, Nantes, France
6 SFR Santé, CNRS, Inserm, Inserm UMS 016, CNRS UMS 3556, Université de Nantes, CHU Nantes, 44000 Nantes
Cancer Immunology, Immunotherapy (2021) - https://doi.org/10.1007/s00262-021-02961-0
An easy and reliable whole blood freezing method for flow cytometry immuno-phenotyping and functional analyses.
Cecile Braudeau a, b, Nina Salabert-Le Guen a, b,Chevreuil Justine a, b, Rimbert Marie a, b, Jerome C. Martin a, b, Regis Josien a, b
a Laboratoire d’Immunologie, CIMNA, LabEx IGO "Immunotherapy, Graft, Oncology", F-44000 Nantes, France
b CHU Nantes, Nantes Université, Inserm, Centre de Recherche en Transplantation et Immunologie, UMR 1064, ITUN, F-44000 Nantes, France
Cystathionine-gamma-lyase overexpression in T cells enhances anti- tumor effect independently of cysteine autonomy.
2LabEx IGO “Immunotherapy, Graft,Oncology”, Nantes, France
3Faculty of Sciences, Tunis, University of Tunis El Manar, Tunis, Tunisia
4Molecular Modeling Group, SIB Swiss Institute for Bioinformatics, Lausanne, Switzerland
5The Ludwig Institute for Cancer Research, University of Lausanne, Epalinges, Switzerland
6Department of Oncology, University of Lausanne and Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
Anti-Tumor Efficacy of PD-L1 Targeted Alpha-Particle Therapy in a Human Melanoma Xenograft Model
Marisa Capitao 1, Justine Perrin1, Sylvain Simon1, Sébastien Gouard1, Nicolas Chouin2, Frank Bruchertseifer3, Alfred Morgenstern3, Latifa Rbah-Vidal1, Michel Chérel4, Emmanuel Scotet1, Nathalie Labarrière1, Yannick Guilloux1 and Joëlle Gaschet1*
1 Université de Nantes, CNRS, Inserm, CRCINA, F-44000 Nantes, France
2 Université de Nantes, CNRS, Inserm, Oniris, CRCINA, F-44000 Nantes, France
3 European Commission, Joint Research Centre, Directorate for Nuclear Safety and Security, G-76344 Karlsruhe, Germany
4 Université de Nantes, CNRS, Inserm, ICO Gauducheau, GIP Arronax, CRCINA, F-44000 Nantes, France
Cancers 2021, 13(6), 1256; https://doi.org/10.3390/cancers13061256
Mechanisms of autoimmune hepatitis
Cardon, Anaïs; Conchon, Sophie∗; Renand, AmédéeUniversité de Nantes, Inserm, Centre de Recherche en Transplantation et Immunologie, UMR 1064, ITUN, Nantes, France
doi: 10.1097/MOG.0000000000000704
Anti-tumor efficacy of a combination therapy with PD-L1 targeted alpha therapy and adoptive cell transfer of PD-1 deficient melanoma-specific human T-lymphocytes
L Marottea,b*, M Capitaoa,b*, C Deleinea,b, T Beauvaisb,c, G Cadioua,b, J. Perrina,b, M Chéreld,e,f, E Scoteta,b, Y Guillouxa,b, F Bruchertseiferg, A Morgensterng, A Jarrya,b, J. Gascheta,b*, and N Labarrierea,b*aUniversité De Nantes, CNRS, INSERM, CRCINA, Nantes, France;
bLabEx IGO “Immunotherapy, Graft, Oncology”, Nantes, France;
cUniversité De Nantes, CNRS, INSERM, CRCINA, CHU of Nantes, Nantes, France;
dUniversité De Nantes, CNRS, INSERM, CRCINA, ICO Gauducheau, Nantes, France;
eLabEx IRON “Innovative Radiopharmaceuticals in Oncology and Neurology”, Nantes, France;
fGIP Arronax, Saint-Herblain, France; gEuropean Commission, Joint Research Centre (JRC), Karlsruhe, Germany
OncoImmunology, 10:1, 1940676, DOI: 10.1080/2162402X.2021.1940676